ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 926-950 of 1,000 matching filings.

Per page
25
Current page
38
6-K File 001-11960

IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL

Filing date
12 Dec 2019
Reporting date
12 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE

Filing date
11 Dec 2019
Reporting date
11 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV

Filing date
05 Dec 2019
Reporting date
05 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA

Filing date
03 Dec 2019
Reporting date
03 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
02 Dec 2019
Reporting date
02 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Dec 2019
Reporting date
02 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE

Filing date
29 Nov 2019
Reporting date
29 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM

Filing date
21 Nov 2019
Reporting date
21 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D

Filing date
15 Nov 2019
Reporting date
15 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB

Filing date
14 Nov 2019
Reporting date
14 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE

Filing date
12 Nov 2019
Reporting date
12 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I

Filing date
12 Nov 2019
Reporting date
12 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE

Filing date
08 Nov 2019
Reporting date
08 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
F-3ASR File 333-234586

FORM F-3ASR

Filing date
08 Nov 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN

Filing date
06 Nov 2019
Reporting date
06 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Nov 2019
Reporting date
01 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA

Filing date
30 Oct 2019
Reporting date
30 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED

Filing date
28 Oct 2019
Reporting date
28 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D

SC 13D

Filing date
25 Oct 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS

Filing date
24 Oct 2019
Reporting date
24 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU

Filing date
21 Oct 2019
Reporting date
21 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT

Filing date
17 Oct 2019
Reporting date
17 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-39067

FORM 4 SUBMISSION

Filing date
09 Oct 2019
Reporting date
07 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
3/A File 001-39067

FORM 3/A SUBMISSION

Filing date
09 Oct 2019
Reporting date
02 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
04 Oct 2019
Reporting date
04 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .